# PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

> **NCT06607627** · PHASE3 · RECRUITING · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 12 (estimated)

## Conditions studied

- Generalized Myasthenia Gravis
- gMG

## Interventions

- **COMBINATION_PRODUCT:** Gefurulimab

## Key facts

- **NCT ID:** NCT06607627
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-13
- **Primary completion:** 2026-12-15
- **Final completion:** 2029-01-23
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06607627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06607627, "PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06607627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*